EA019970B8 - Производные имидазолидиндиона - Google Patents
Производные имидазолидиндионаInfo
- Publication number
- EA019970B8 EA019970B8 EA201290310A EA201290310A EA019970B8 EA 019970 B8 EA019970 B8 EA 019970B8 EA 201290310 A EA201290310 A EA 201290310A EA 201290310 A EA201290310 A EA 201290310A EA 019970 B8 EA019970 B8 EA 019970B8
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disorders
- imidazolidinedione derivatives
- provides
- salts
- imidazolidinedione
- Prior art date
Links
- 150000001468 imidazolidinediones Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000016621 Hearing disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0921760A GB0921760D0 (en) | 2009-12-11 | 2009-12-11 | Novel compounds |
| GBGB1012924.5A GB201012924D0 (en) | 2010-07-30 | 2010-07-30 | Novel compounds |
| PCT/EP2010/068946 WO2011069951A1 (en) | 2009-12-11 | 2010-12-06 | Imidazolidinedione derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201290310A1 EA201290310A1 (ru) | 2013-01-30 |
| EA019970B1 EA019970B1 (ru) | 2014-07-30 |
| EA019970B8 true EA019970B8 (ru) | 2014-11-28 |
Family
ID=43446689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290310A EA019970B8 (ru) | 2009-12-11 | 2010-12-06 | Производные имидазолидиндиона |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8722695B2 (enExample) |
| EP (1) | EP2509961B1 (enExample) |
| JP (1) | JP5788404B2 (enExample) |
| KR (1) | KR101735675B1 (enExample) |
| CN (1) | CN102753533B (enExample) |
| AU (1) | AU2010330048B9 (enExample) |
| BR (1) | BR112012015868A2 (enExample) |
| CA (1) | CA2781685C (enExample) |
| DK (1) | DK2509961T3 (enExample) |
| EA (1) | EA019970B8 (enExample) |
| ES (1) | ES2575215T3 (enExample) |
| IL (1) | IL219628A (enExample) |
| MX (1) | MX2012006615A (enExample) |
| PL (1) | PL2509961T3 (enExample) |
| WO (1) | WO2011069951A1 (enExample) |
| ZA (1) | ZA201203233B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8519176B1 (en) * | 2009-10-05 | 2013-08-27 | Boehringer Ingelheim International Gmbh | Process for preparation of substituted P-aminophenol |
| CA2781685C (en) * | 2009-12-11 | 2018-09-04 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| PL2624695T3 (pl) | 2010-10-08 | 2016-03-31 | Nivalis Therapeutics Inc | Nowe podstawione związki chinolinowe jako inhibitory reduktazy S-nitrozoglutationu |
| US9346790B2 (en) | 2010-12-06 | 2016-05-24 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
| WO2013083994A1 (en) | 2011-12-06 | 2013-06-13 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| US9193704B2 (en) | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| BR112014028991A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
| US9669030B2 (en) * | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
| WO2013182851A1 (en) * | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| HUE041418T2 (hu) * | 2013-08-29 | 2019-05-28 | Kyoto Pharma Ind | Aromás vegyületek és alkalmazásuk csont metabolizmushoz kapcsolódó rendellenességek kezelésére |
| EP3372586A1 (en) * | 2014-12-19 | 2018-09-12 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| CN105837453A (zh) * | 2016-03-31 | 2016-08-10 | 常州大学 | 一种3,5-二氯-4’-硝基二苯醚的合成方法 |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| CN108101811A (zh) * | 2016-11-25 | 2018-06-01 | 斯福瑞（南通）制药有限公司 | 生产n-叔丁氧羰基-2-氨基-3,3-二甲基丁酸的方法 |
| EP3555073A1 (en) | 2016-12-16 | 2019-10-23 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| TW201904947A (zh) | 2017-05-02 | 2019-02-01 | 美商富曼西公司 | 作為除草劑的嘧啶氧基苯稠合化合物 |
| WO2018220762A1 (ja) | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| US12090146B2 (en) | 2018-09-21 | 2024-09-17 | Bionomics Limited | Substituted-pyridinyl compounds and uses thereof |
| HUE068686T2 (hu) | 2018-10-16 | 2025-01-28 | Autifony Therapeutics Ltd | Új vegyületek |
| US12358901B2 (en) | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| JP6870064B2 (ja) * | 2018-11-30 | 2021-05-12 | 大塚製薬株式会社 | ピリミジン化合物の医薬用途 |
| TWI877067B (zh) | 2018-11-30 | 2025-03-11 | 日商大塚製藥股份有限公司 | 雜環化合物 |
| EP3947365B1 (en) * | 2019-03-25 | 2025-10-01 | Bionomics Limited | Substituted-n-heteroaryl compounds and uses thereof |
| PH12022551955A1 (en) | 2020-02-06 | 2023-10-23 | Autifony Therapeutics Ltd | Novel compound |
| EP3901152A1 (en) * | 2020-04-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Kv3 enhancers for the treatment of cognitive disorders |
| GB2594931A (en) * | 2020-05-06 | 2021-11-17 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
| AU2022327657A1 (en) | 2021-08-10 | 2024-02-01 | Autifony Therapeutics Limited | Potassium channel modulators |
| CN114605331A (zh) * | 2022-03-17 | 2022-06-10 | 上海健康医学院 | 一种尼鲁米特及其中间体的制备方法 |
| EP4499614A1 (de) * | 2022-03-28 | 2025-02-05 | Bayer Aktiengesellschaft | Substituierte 2-aminoazine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| WO2024121552A1 (en) | 2022-12-06 | 2024-06-13 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| EP0726898B1 (en) * | 1993-11-01 | 2000-12-20 | H. Lundbeck A/S | Phenylindole compounds |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1147725A (en) * | 1966-03-30 | 1969-04-02 | Mitsui Kagaku Kogyo Kabushiki | Novel halodiphenylethers for use as herbicides |
| US4099007A (en) * | 1969-04-02 | 1978-07-04 | Hoechst Aktiengesellschaft | N,n-substituted 2,4,5-triketoimidazolidines and a process for their preparation |
| DE2916647A1 (de) * | 1979-04-25 | 1980-11-06 | Basf Ag | Parabansaeurederivate |
| DE3015090A1 (de) | 1980-04-19 | 1981-10-22 | Basf Ag, 6700 Ludwigshafen | ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen |
| DE3133405A1 (de) | 1981-08-24 | 1983-03-10 | Basf Ag, 6700 Ludwigshafen | 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide |
| JP2514945B2 (ja) | 1987-02-05 | 1996-07-10 | 三井石油化学工業株式会社 | 芳香族アミン誘導体 |
| DE3810848A1 (de) | 1988-03-30 | 1989-10-19 | Boehringer Ingelheim Kg | Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung |
| DE3836175A1 (de) | 1988-10-24 | 1990-05-03 | Bayer Ag | Fluor enthaltende phenole |
| WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
| US5362878A (en) | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
| FR2706456B1 (fr) * | 1993-06-18 | 1996-06-28 | Rhone Poulenc Agrochimie | Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides. |
| US6002016A (en) * | 1991-12-20 | 1999-12-14 | Rhone-Poulenc Agrochimie | Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones |
| AU5639096A (en) | 1995-05-17 | 1996-11-29 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| WO1996036229A1 (en) | 1995-05-17 | 1996-11-21 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
| JPH11508257A (ja) | 1995-06-20 | 1999-07-21 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 殺節足動物性及び殺菌・殺カビ性環式アミド |
| WO1998005652A2 (en) | 1996-08-01 | 1998-02-12 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| EP0944314A1 (en) | 1996-11-26 | 1999-09-29 | E.I. Du Pont De Nemours And Company | Methyl substituted fungicides and arthropodicides |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| AU6040398A (en) | 1997-01-30 | 1998-08-25 | E.I. Du Pont De Nemours And Company | Fungicidal compositions |
| SI0966436T1 (en) * | 1997-02-21 | 2003-04-30 | Bayer Aktiengesellschaft | Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases |
| JP4171549B2 (ja) | 1998-01-28 | 2008-10-22 | 大正製薬株式会社 | 含フッ素アミノ酸誘導体 |
| AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | ６−フルオロビシクロ［３．１．０］ヘキサン誘導体 |
| JP2000072731A (ja) | 1998-08-31 | 2000-03-07 | Taisho Pharmaceut Co Ltd | ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物 |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| CN1364080A (zh) | 1999-07-23 | 2002-08-14 | 盐野义制药株式会社 | Th2分化抑制剂 |
| CA2404381A1 (en) | 2000-04-04 | 2002-09-26 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
| WO2001076582A1 (fr) | 2000-04-05 | 2001-10-18 | Shionogi & Co., Ltd. | Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci |
| FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
| GB0026838D0 (en) | 2000-11-02 | 2000-12-20 | Glaxo Group Ltd | Treatment method |
| JPWO2003048134A1 (ja) | 2001-12-05 | 2005-04-14 | 日本たばこ産業株式会社 | トリアゾール化合物及びその医薬用途 |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| CA2475767A1 (en) | 2002-02-07 | 2003-08-14 | The Curators Of The University Of Missouri | Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds |
| JP4623279B2 (ja) * | 2002-05-16 | 2011-02-02 | メリアル・リミテッド | ピリジンカルボキサミド誘導体および農薬としてのその使用 |
| EP1618094B1 (en) | 2003-04-30 | 2007-09-05 | The Institutes for Pharmaceutical Discovery, LLC | Substituted heteroaryls as inhibitors of protein tyrosine phosphatases |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| GB0325175D0 (en) | 2003-10-28 | 2003-12-03 | Novartis Ag | Organic compounds |
| US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
| GB0413879D0 (en) | 2004-06-21 | 2004-07-21 | Glaxo Group Ltd | Compounds |
| US20060211697A1 (en) | 2004-12-08 | 2006-09-21 | Liren Huang | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents |
| DE102005001411A1 (de) | 2005-01-12 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| NZ561042A (en) | 2005-02-18 | 2011-03-31 | Novartis Vaccines & Diagnostic | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052 |
| AU2007245022A1 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| KR101332889B1 (ko) | 2005-05-13 | 2013-11-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| US20100113959A1 (en) | 2006-03-07 | 2010-05-06 | Beth Israel Deaconess Medical Center, Inc. | Transcranial magnetic stimulation (tms) methods and apparatus |
| EP4385574A3 (en) | 2006-03-27 | 2024-10-02 | The Regents of the University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| JP2010524970A (ja) | 2007-04-20 | 2010-07-22 | デシフェラ ファーマシューティカルズ，エルエルシー | 骨髄増殖性疾患及びその他の増殖性疾患の治療に有用なキナーゼ阻害剤 |
| WO2009097997A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| EP2252592A1 (de) | 2008-02-07 | 2010-11-24 | Sanofi-Aventis | Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
| SG172778A1 (en) | 2008-12-22 | 2011-08-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| EP2445334A1 (en) | 2009-06-26 | 2012-05-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non human animal models for increased retinal vascular permeability |
| CA2781685C (en) | 2009-12-11 | 2018-09-04 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| CA2780526A1 (en) | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US9346790B2 (en) * | 2010-12-06 | 2016-05-24 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
| US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| US9193704B2 (en) * | 2011-06-07 | 2015-11-24 | Autifony Therapeutics Limited | Hydantoin derivatives as KV3 inhibitors |
| BR112014028991A2 (pt) * | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | triazóis como inibidores de kv3 |
| US9669030B2 (en) * | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
-
2010
- 2010-12-06 CA CA2781685A patent/CA2781685C/en not_active Expired - Fee Related
- 2010-12-06 ES ES10788314.2T patent/ES2575215T3/es active Active
- 2010-12-06 WO PCT/EP2010/068946 patent/WO2011069951A1/en not_active Ceased
- 2010-12-06 CN CN201080056084.0A patent/CN102753533B/zh not_active Expired - Fee Related
- 2010-12-06 KR KR1020127018080A patent/KR101735675B1/ko not_active Expired - Fee Related
- 2010-12-06 MX MX2012006615A patent/MX2012006615A/es active IP Right Grant
- 2010-12-06 PL PL10788314.2T patent/PL2509961T3/pl unknown
- 2010-12-06 EA EA201290310A patent/EA019970B8/ru not_active IP Right Cessation
- 2010-12-06 US US13/515,097 patent/US8722695B2/en active Active
- 2010-12-06 BR BR112012015868A patent/BR112012015868A2/pt active Search and Examination
- 2010-12-06 JP JP2012542487A patent/JP5788404B2/ja not_active Expired - Fee Related
- 2010-12-06 EP EP10788314.2A patent/EP2509961B1/en active Active
- 2010-12-06 AU AU2010330048A patent/AU2010330048B9/en not_active Ceased
- 2010-12-06 DK DK10788314.2T patent/DK2509961T3/en active
-
2012
- 2012-05-04 ZA ZA2012/03233A patent/ZA201203233B/en unknown
- 2012-05-07 IL IL219628A patent/IL219628A/en active IP Right Grant
-
2014
- 2014-03-27 US US14/226,988 patent/US9216967B2/en active Active
-
2015
- 2015-11-09 US US14/935,939 patent/US20160058737A1/en not_active Abandoned
-
2016
- 2016-11-10 US US15/348,091 patent/US9849131B2/en active Active
-
2017
- 2017-10-02 US US15/722,623 patent/US10058551B2/en active Active
-
2018
- 2018-07-30 US US16/049,230 patent/US10632118B2/en active Active
-
2020
- 2020-01-30 US US16/777,668 patent/US20200163964A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675403A (en) * | 1985-10-16 | 1987-06-23 | American Home Products Corporation | 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity |
| EP0726898B1 (en) * | 1993-11-01 | 2000-12-20 | H. Lundbeck A/S | Phenylindole compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA019970B8 (ru) | Производные имидазолидиндиона | |
| MX2018015635A (es) | Composiciones y metodos para la modulacion de division de smn2 en un sujeto. | |
| GEP20156216B (en) | Heterocyclic compound and usage thereof | |
| PH12015502708A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| MX2012003539A (es) | Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac). | |
| PH12012500940B1 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| PH12012500938A1 (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| TN2011000209A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| PL1979355T3 (pl) | Pochodne spiro imidazoli jako modulatory PPAR | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| PL2150530T3 (pl) | Podstawione pochodne sulfonamidu | |
| MX2009003316A (es) | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. | |
| EP2166837A4 (en) | DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS | |
| MX2009011712A (es) | Formulaciones mejoradas de lamotrigina. | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| SI2024368T1 (sl) | Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine | |
| NZ600874A (en) | Fluorinated derivatives of deferiprone | |
| MX2010006204A (es) | Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| WO2008052139A3 (en) | Ultra low dose doxepin and methods of using the same to treat sleep disorders | |
| WO2007131907A3 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| UA106200C2 (uk) | Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину | |
| UA109793C2 (uk) | Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG MD TJ TM |